0 (0%)		11-11 17:45
Open: High: Volume: 0		Pre. Close: Low: Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	210.06	1-year :	245.35
Resists	First :	179.85	Second :	210.06
Pivot price	178.75
Supports	First :	178.21	Second :	177.19
MAs	MA(5) :	178.75	MA(20) :	178.75
	MA(100) :	170.29	MA(250) :	144.27
MACD	MACD :	0.2	Signal :	0.28
%K %D	K(14,3) :	58.49	D(3) :	58.49
RSI	RSI(14): 71.18
52-week	High :	189.99	Low :	111.75

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

Fri, 29 Apr 2022
HEROES mentorship program counsels high school students on college preparation - The Lamron

Tue, 23 Nov 2021
Merck Completes Acquisition of Acceleron Pharma - Nasdaq

Mon, 22 Nov 2021
Merck Closes Deal for Acceleron Pharma, Biggest Biotech Merger of the Year - Barron's

Tue, 09 Nov 2021
Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer - Business Wire

Thu, 30 Sep 2021
Merck to buy Acceleron for about $11.5 bln in rare disease drug push - Reuters

Tue, 28 Jan 2020
Acceleron Stock Is Skyrocketing After Surprise Success for Heart Drug - Barron's

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange:
Sector:
Industry:
Shares Out	61 (M)
Shares Float	50 (M)
Held by Insiders	11.7 (%)
Held by Institutions	91.4 (%)
Shares Short	1,680 (K)
Shares Short P.Month	1,980 (K)

EPS	-3.72
EPS Est Next Qtrly	-0.64
EPS Est This Year	-2.7
EPS Est Next Year	-2.28
Book Value (p.s.)	12.56
Profit Margin	-221.14 %
Operating Margin	-221.59 %
Return on Assets (ttm)	-21.3 %
Return on Equity (ttm)	-37.76 %
Qtrly Rev. Growth	-29.71 %
Gross Profit (p.s.)	-1.34
Sales Per Share	1.65
EBITDA (p.s.)	-3.61
Qtrly Earnings Growth	0 %
Operating Cash Flow	-193 (M)
Levered Free Cash Flow	-108 (M)

PE Ratio	-48.19
PEG Ratio	0
Price to Book value	14.23
Price to Sales	108.04
Price to Cash Flow	-0.01

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.